These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31672704)

  • 21. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8
    Lake CM; Voss K; Bauman BM; Pohida K; Jiang T; Dveksler G; Snow AL
    Cell Death Dis; 2021 Apr; 12(4):400. PubMed ID: 33854046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
    Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
    Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
    Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Galectin-9-related immune checkpoint receptors in B-cell acute lymphoblastic leukemia.
    Akbar A; Asgarian-Omran H; Valadan R; Dindarloo MM; Najafi A; Kahrizi A; Poursheikhani A; Karami H; Naderi M; Sabeti S; Tehrani M
    Iran J Basic Med Sci; 2023; 26(12):1468-1474. PubMed ID: 37970435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VISTA expression and patient selection for immune-based anticancer therapy.
    Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
    Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging immune checkpoints for cancer therapy.
    Li X; Hu W; Zheng X; Zhang C; Du P; Zheng Z; Yang Y; Wu J; Ji M; Jiang J; Wu C
    Acta Oncol; 2015 Nov; 54(10):1706-13. PubMed ID: 26361073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VISTA is an immune checkpoint molecule for human T cells.
    Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
    Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
    Takamatsu K; Tanaka N; Hakozaki K; Takahashi R; Teranishi Y; Murakami T; Kufukihara R; Niwa N; Mikami S; Shinojima T; Sasaki T; Sato Y; Kume H; Ogawa S; Kakimi K; Kamatani T; Miya F; Tsunoda T; Aimono E; Nishihara H; Sawada K; Imamura T; Mizuno R; Oya M
    Nat Commun; 2021 Sep; 12(1):5547. PubMed ID: 34545095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
    Tobin JWD; Bednarska K; Campbell A; Keane C
    Cells; 2021 May; 10(5):. PubMed ID: 34068762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R
    Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis.
    Wang YQ; Zhang Y; Jiang W; Chen YP; Xu SY; Liu N; Zhao Y; Li L; Lei Y; Hong XH; Liang YL; Li JY; Zhang LL; Yun JP; Sun Y; Li YQ; Ma J
    J Immunother Cancer; 2019 Nov; 7(1):298. PubMed ID: 31722750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of activating natural killer-cell receptors is a hallmark of the innate-like T-cell neoplasm in peripheral T-cell lymphomas.
    Uemura Y; Isobe Y; Uchida A; Asano J; Nishio Y; Sakai H; Hoshikawa M; Takagi M; Nakamura N; Miura I
    Cancer Sci; 2018 Apr; 109(4):1254-1262. PubMed ID: 29363227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VISTA: A Novel Checkpoint for Cancer Immunotherapy.
    Gao Y; He Y; Tang Y; Chen ZS; Qu M
    Drug Discov Today; 2024 Jul; 29(7):104045. PubMed ID: 38797321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma.
    Deng WW; Wu L; Sun ZJ
    Oral Dis; 2018 Mar; 24(1-2):120-123. PubMed ID: 29480599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VISTA expressed in tumour cells regulates T cell function.
    Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M
    Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma.
    Wang Y; Deng J; Wang L; Zhou T; Yang J; Tian Z; Yang J; Chen H; Tang X; Zhao S; Zhou L; Tong A; Xu J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes.
    Shokrgozar N; Dehghani M; Golmoghaddam H; Moghadam M; Rezaei N; Moayed V; Arandi N
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e388-e397. PubMed ID: 35098660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.